Kawai Kosuke, Gebremeskel Berhanu G, Acosta Camilo J
Global Health Outcomes, Merck & Co., Inc., West Point, Pennsylvania, USA.
School of Public Health, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA.
BMJ Open. 2014 Jun 10;4(6):e004833. doi: 10.1136/bmjopen-2014-004833.
The objective of this study was to characterise the incidence rates of herpes zoster (HZ), also known as shingles, and risk of complications across the world.
We systematically reviewed studies examining the incidence rates of HZ, temporal trends of HZ, the risk of complications including postherpetic neuralgia (PHN) and HZ-associated hospitalisation and mortality rates in the general population. The literature search was conducted using PubMed, EMBASE and the WHO library up to December 2013.
We included 130 studies conducted in 26 countries. The incidence rate of HZ ranged between 3 and 5/1000 person-years in North America, Europe and Asia-Pacific, based on studies using prospective surveillance, electronic medical record data or administrative data with medical record review. A temporal increase in the incidence of HZ was reported in the past several decades across seven countries, often occurring before the introduction of varicella vaccination programmes. The risk of developing PHN varied from 5% to more than 30%, depending on the type of study design, age distribution of study populations and definition. More than 30% of patients with PHN experienced persistent pain for more than 1 year. The risk of recurrence of HZ ranged from 1% to 6%, with long-term follow-up studies showing higher risk (5-6%). Hospitalisation rates ranged from 2 to 25/100 000 person-years, with higher rates among elderly populations.
HZ is a significant global health burden that is expected to increase as the population ages. Future research with rigorous methods is important.
本研究的目的是描述世界各地带状疱疹(HZ,又称缠腰龙)的发病率以及并发症风险。
我们系统回顾了有关HZ发病率、HZ的时间趋势、并发症风险(包括带状疱疹后神经痛(PHN)以及HZ相关的住院率和普通人群死亡率)的研究。截至2013年12月,使用PubMed、EMBASE和世界卫生组织图书馆进行文献检索。
我们纳入了在26个国家开展的130项研究。基于采用前瞻性监测、电子病历数据或带有病历审查的行政数据的研究,北美、欧洲和亚太地区的HZ发病率在每1000人年3至5例之间。过去几十年间,七个国家报告了HZ发病率呈时间性上升,这种情况通常发生在水痘疫苗接种计划实施之前。发生PHN的风险从5%到超过30%不等,这取决于研究设计类型、研究人群的年龄分布和定义。超过30%的PHN患者经历了持续1年以上的疼痛。HZ复发风险在1%至6%之间,长期随访研究显示风险更高(5 - 6%)。住院率在每100000人年2至25例之间,老年人群中的住院率更高。
HZ是一项重大的全球健康负担,预计随着人口老龄化还会增加。采用严谨方法开展未来研究很重要。